RecurX Bio

RecurX Bio is a private oncology-focused diagnostics and research tools company formed to commercialize a patented microfluidic phenotypic assay developed from Johns Hopkins research. The company has described its platform as capturing the metastatic cancer cell subpopulation most responsible for recurrence and spread, with applications in prognostic testing, treatment-response prediction, and drug discovery. Public descriptions indicate an initial focus on breast cancer and glioblastoma, and on helping oncologists and biopharma developers identify more effective anti-metastatic therapies before treatment or clinical trials begin. Available evidence suggests the business remained at the preclinical or early commercialization stage rather than advancing a therapeutic drug pipeline. Third-party databases in 2025 characterized the company as inactive or deadpooled, while the current website appears minimal and does not show an operating product portfolio.